The adaptive immune system, including type1 helper T cells (Th1 cells), cytotoxic T lymphocytes (CTLs), and dendritic cells (DCs), plays an important role in the control of hepatitis B virus (HBV). On the other hand, regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) suppress the immune reaction in HBV and hepatocellular carcinoma (HCC). Excessive activation of immune suppressive cells could contribute to the persistent infection of HBV and the progression of HCC. The frequency and/or function of Tregs could affect the natural course in chronic hepatitis B patients and the treatment response. In addition to the suppressive function of MDSCs, MDSCs could affect the induction and function of Tregs. Therefore, we should understand in detail the mechanism by which Tregs and MDSCs are induced to control HBV persistent infection and HBV-related HCC. Immune suppressive cells, including Tregs and MDSCs, contribute to the difficulty in inducing an effective immune response for HBV persistent infection and HBV-related HCC. In this review, we focus on the Tregs and MDSCs that could be potential targets for immune therapy of chronic hepatitis B and HBV-related HCC.
Introduction
Hepatitis B virus (HBV) is a noncytopathic DNA virus that causes chronic hepatitis and hepatocellular carcinoma (HCC) as well as acute hepatitis [1] . HBV infects more than 400 million people worldwide. HBV has six different genotypes [2, 3] . The progression of liver fibrosis and HCC could vary among various HBV genotypes [3, 4] .
It has been reported that the innate immune system, including intra-hepatocyte reactions [5, 6] , natural killer cells (NK cells), natural killer T cells (NK-T cells), and monocytes, could contribute to the immunopathogenesis of HBV infection [7] [8] [9] [10] [11] [12] . However, the adaptive immune system, including type 1 helper T cells (Th1 cells), cytotoxic T lymphocytes (CTLs), and dendritic cells (DCs), plays an important role in the control of HBV [13] [14] [15] [16] [17] [18] . On the other hand, CD4 T lymphocytes and has a broad repertoire that recognizes various self and non-self antigens [26] [27] [28] . Various kinds of immune suppressing mechanisms-induced by Tregs have been reported [28] . The important mechanisms are cell-to-cell contact and secretion of immune-suppressive cytokines including transforming growth factor-β (TGF-β) and IL10 [19, 23, 28 ]. An emerging cell population of interest, MDSCs, could contribute to immune suppression. MDSCs are a heterogeneous population of immature myeloid cells, originally shown to accumulate at the sites of tumors. MDSCs have been well described in various severe human diseases such as cancer, autoimmune diseases, and bacterial infections [19, 29, 30] . In mouse, populations of MDSCs have been divided into two groups: polymorphonuclear MDSCs (PMN-MDSC), described as CD11b (Table 1) . It has been reported that MDSCs could contribute to persistent infection of HBV and HCC [19, 20, 30, [33] [34] [35] [36] [37] [38] (Table 1) . In addition to HBV and HCC, MDSCs could contribute to persistent infection of HCV [39, 40] . HCV core-treated CD33 phenotype with up-regulated reactive oxygen species (ROS) production [39] . Moreover, the frequency of MDSCs increases and correlates with HCV-RNA loads in chronic hepatitis C (CH-C) patients [40] . MDSCs could suppress the T cell response by way of numerous mechanisms including the expression of inhibitory cell surface molecules, the production of immune suppressive cytokines, the metabolism of arginine through activation of arginase-1, production of nitric oxide, and the up-regulation of reactive oxygen species. Moreover, an interaction between MDSCs and Tregs has been reported [20, 31, 32, [41] [42] [43] . MDSCs and Tregs could contribute to not only HCC but also various kinds of cancers (Table 2) . Many groups reported the frequency of MDSCs, and Tregs could be useful prognostic biomarkers. Moreover, some reports indicated the possibility of modifying the function of MDSCs and Tregs to improve the immune reaction to cancers by using CTLA-4 antibody, PD-L1 antibody, anti-miR214, c-kit antibody and sunitinib, etc. (Table 2) . Glioblastoma ○ prognostic marker Soyour E et al. [62] Colon carcinoma (mouse model) ○ ○ c-kit antibody Pan et al. [63] Recently, nucleoside analogues have emerged as an important treatment option for chronic hepatitis B patients [64] . However, discontinuation of nucleoside analogues could frequently induce the reactivation of chronic hepatitis [65, 66] . Therefore, pegylated interferon (Peg-IFN) could be a significant treatment to control replication of HBV by inducing an immune response. The efficacy of Peg-IFN treatment has not yet become optimal [67] . Immune suppressive cells including Tregs and MDSCs might contribute to the difficulty of inducing an effective immune response for HBV persistent infection and HCC. This review focuses on the Tregs and MDSCs that could be potential targets for the immune therapy of chronic hepatitis B patients and HCC.
Tregs Could Affect HBV Persistent Infection
In addition to hepatitis c virus infection (HCV), it has been reported that the HBV-specific immune response could be suppressed by CD4 + CD25 + Tregs in patients with HBV infection [68] . This report indicated that not only Tregs from CH-B patients, but also those from patients with resolved HBV infection could suppress HBV specific CD8 + T cell. However, it has been reported that the frequency of Tregs in CH-B patients was significantly higher than those in healthy controls and those with resolved HBV infection [69] . Therefore, the frequency of Tregs might contribute to the disease status of HBV infection [23, 24, [68] [69] [70] [71] [72] [73] [74] [75] [76] (Table 3) . Tregs have been identified by using CD4, CD25, CD45RO and CTLA-4 antibodies. Another group reported that the frequency of CD39 Moreover, the depletion of Tregs could recover the function of IFN-gamma secretion of CD4 + T cells in an ex vivo study [23] . Another group reported a similar phenomenon and the enhancement of HBV-specific T cell proliferation after the depletion of Tregs [69] . Previously, several groups including ours reported that the reduction of HBV could recover the frequency of HBV-specific T cells and the function of T cells [15, 78] . Tregs might contribute to suppressing the HBV-specific T cells. Therefore, treatment with a nucleos(t)ide analogue might affect the Tregs. Previously, Stoop et al. [71] described that adefovir-induced viral load reduction caused a decrease in circulating Tregs together with a partial recovery of the immune response. They described that the frequency of Tregs among CD4 + T cells was decreased at three and six months after adefovir treatment. Moreover, they determined that the frequency of HBcAg-specific IFN-gamma secreting cells was increased during adefovir treatment. We also reported that the entecavir-induced viral load reduction caused a decrease in circulating Tregs [24] . Moreover, we analyzed the mechanism of Tregs enhancement of functions in chronic hepatitis B patients [24] . + ratio than that in chronic liver failure patients [87] . Another report described that a lower Treg/Th17 ratio induced greater liver fibrosis progression [88] . Although these findings are unsurprising, the balance between Tregs and Th17 might be usefully analyzed for the disease status and treatment response. A group described that the frequency of Tregs increased in non-responders but not in responders during pegylated-interferon [91] . The frequency and/or function of Tregs could affect the natural course of chronic hepatitis B patients and treatment response [92] . Most of the groups analyzed the peripheral blood to detect Tregs (Table 3) . Some groups analyzed liver-infiltrating lymphocytes in addition to peripheral blood to detect Tregs. Xu et al. [70] indicated that the frequency of liver-infiltrating Tregs increased in CH-B patients and chronic severe hepatitis B patients, as seen in peripheral blood. Yang et al. [72] reported that Foxp3+ cells were present in significantly higher numbers in liver tissue sections from chronic active hepatitis B, as seen in peripheral blood. However, it is difficult to carry out the sequential analysis of liver-infiltrating lymphocytes since liver biopsy has a risk of bleeding. 
Concluding Remarks
Many groups including ours have reported that Tregs and MDSCs suppress the immune reaction for HBV and HCC. The excessive activation of immune suppressive cells could contribute to the persistent infection of HBV and the progression of HCC. Therefore, detailed mechanisms of the induction of Tregs and MDSCs should be investigated to control HBV persistent infection and HBV-related HCC. Moreover, the ability to specifically suppress Tregs and MDSCs, and understanding the appropriate time point to do so, might improve the treatment of HBV-related diseases.
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